• T.V.S. Geethika Avanthi Institute of Pharmaceutical Sciences, Cherukupally (v), Bhogapuram (m), near Tagarapuvalasa bridge, Vizianagaram district, Andhra Pradesh.
  • Shailendra Kodat School of pharmaceutical sciences, Lovely Professional University, Jalandhar-G.T road, Phagwara, Punjab- 144411.
  • N. Thanusha Avanthi Institute of Pharmaceutical Sciences, Cherukupally (v), Bhogapuram (m), near Tagarapuvalasa bridge, Vizianagaram district, Andhra Pradesh.


Interstitial lung disease is a condition that causes gradual scarring of the lung tissue. This may be due to some chemical exposure or even due to substances like coal and asbestos dust. It may also tesult from auto immune conditions such as rheumatoid arthritis. The scarring which occurs in this condition is usually irreversible. The common symptoms of this condition includes dry cough and SOB on exertion. The diagnostic procedures include HRCT chest imaging, blood tests, bronchoscopy, bronchoalveolar lavage , pulmonary function tests and rarely surgical biopsy. The basic first line therapy includes corticosteroids, DMARDs based on the condition and type of ILD in the individual patient followed by a lung transplant if needed.

Keywords: Interstitial Lung Disease, HRCT Chest Imaging, Disease Modifying Anti Rheumatic Drugs (DMARDs)


Download data is not yet available.


1) Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007;4:443–8.
2) Hunninghake, G.W., Fauci, A.S. 1979. Pulmonary involvement in collagen vascular disesases. Am. Rev. Respir. Dis. 119, 471.
3) Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 31:315-324, 1988.
4) Anthony J. Esposito, MDa, Sarah G. Chu, MDa, Rachna Madan, MDb, Tracy J. Doyle, MDa,Paul F. Dellaripa, MD. Thoracic Manifestations of Rheumatoid Arthritis. Clin Chest Med 40 (2019) 545–560
5) Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005;127(6): 2019–27
6) Nannini C, Ryu JH, Matteson EL, Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 2008;20(3):340e6.
7) Margaret Wilsher, Louisa Voight , David Milne , Mark Teh , Nicola Good , John Kolbe , Megan Williams , Karen Pui ,Tony Merriman , Karishma Sidhu , Nicola Dalbeth . Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoidarthritis. Respiratory Medicine (2012) 106, 1441e1446.
8) Walker, W.C., Wright, V. 1968. Pulmonary lesions and rheumatoid arthritis. Medicine 47, 501.
9) Remy-Jardin, M., Remy, J., Cortet, B., Mauri, F., Delcambre, M. 1994. Lung changes in rheumatoid arthritis: CT findings. Radiology 193, 375/.
10) Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/ European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188(6):733–48.
11) Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. Respir Med 2012;106(8):1164–9.
12) Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35(6):1322–8.
13) Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40(10):1829–37.
14) Walden PA, Mitchell-Weggs PF, Coppin C, et al. Pleurisy and methotrexate treatment. Br Med J 1977;2(6091):867.
15) Cannon GW, Ward JR, Clegg DO, et al. Acute lung disease associated with lowdose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983;26(10):1269–74.
16) St Clair EW, Rice JR, Snyderman R. Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis. Arch Intern Med 1985;145(11):2035–8.
17) Gispen JG, Alarcon GS, Johnson JJ, et al. Toxicity of methotrexate in rheumatoid
arthritis. J Rheumatol 1987;14(1):74–9.
18) Amital A, Shitrit D, Adir Y. The lung in rheumatoid arthritis. Presse Med 2011;40(1 Pt 2):e31–48.
19) Toussirot E, Berthelot JM, Pertuiset E, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009;36(11):2421–7.
20) Peno-Green L, Lluberas G, Kingsley T, et al. Lung injury linked to etanercept therapy. Chest 2002;122(5):1858–60.
21) Atzeni F, Boiardi L, Salli S, et al. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. Expert Rev Clin Immunol 2013;9(7): 649–57.
22) Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum 2014;43(5):613–26.
23) Sakai F, Noma S, Kurihara Y, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005;15(3):173–9.
24) Liote H, Liote F, Seroussi B, et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010;35(3):681–7.
25) Parry SD, Barbatzas C, Peel ET, et al. Sulphasalazine and lung toxicity. Eur Respir
J 2002;19(4):756–64.
26) Vassallo R, Thomas CF. Advances in treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol 2004;16(3):186–91
27) King, T.E. Jr. 1998. Interstitial lung diesease. In: M.I. Schwarz, T.E. King, Jr. (Eds.), Connective tissue disease, 3rd edn., BC Decker,Hamilton, Ont., Canada, p. 451.
28) Roschmann, R.A., Rothenberg, R.J. 1987. Pulmonary fibrosis in rheumatoid arthritis: a review of clinical features and therapy.Semin. Arthritis Rheum. 16, 174.
29) Rajasekaran, B.A., Shovlin, D., Lord, P., Kelly, C.A. 2001. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. Rheumatology 40, 1022.
30) Dixon, A.S., Dixon, J., Ball, J. 1957. Honeycomb lung and chronic rheumatoid arthritis. Ann. Rheum. Dis. 16, 241.
31) Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoidarthritis-associated interstitial lung disease. Eur Respir J 2010;35(6):1322–8
32) Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007;175(7):705–11.
33) Shahane A. pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatol Int 2013;77(7):1655-67.
34) Lee HK, Kim DS, YOO B, Seo JB, Rho JY, Colby TV, et al. histopathologic pattern and clinical features of rheumatoid arthritis associated interstitial lung disease. Chest 2005;127:2019-27.
35) Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the I r i s h T h o r a c i c S o c i e t y. T h or a x 2008;63(Suppl. 5):v1-58.
36) Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
37) Akira M, Sakatani M, Hara H. Thin-section CT findings in rheumatoid arthritis–associated lung disease: CT patterns and their courses. J Comput Assist Tomogr 1999;23:941-8.
38) Hunninghake GW, Lynch DA, Galvin JR, Gross BH, Muller N, Schwartz DA et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003;124:1215-23.
39) Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997;156(2 Pt 1): 528-35.
40) Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001;56:622-7
41) Lee-H-K, Kim DS YB. Histopathologic pattern and clinical features of rheumatoidarthritis – associated interstitial lung disease. Chest 2005;127:2019–27. doi:10.1378/chest.127.6.2019..
42) Kelly C, et al., Lung involvement in inflammatory rheumatic diseases, Best Practice & Research Clinical Rheumatology (2016), http://dx.doi.org/10.1016/j.berh.2016.10.004
43) Rekha Vij , MD ; and Mary E. Strek , MD , FCCP . Diagnosis and Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease. Recent Advances in Chest Medicine. DOI: 10.1378/chest.12-0741
44) Mark J. Hamblin and Maureen R. Horton. Rheumatoid Arthritis-Associated Interstitial Lung Disease:Diagnostic Dilemma. Pulmonary Medicine Volume 2011, Article ID 872120, 12 pages doi:10.1155/2011/872120
45) Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. IFIGENIA study group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353(21):2229–42.
46) Mohr M, Jacobi AM. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol 2011;40(5):400–1.
47) Kelly C, Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother 2008;9(18):3221–30.
48) Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg–Strauss syndrome. Ann Rheum Dis 2006;65(8):1116–7.
49) Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 2009;48(1):49–52.
50) Nishimoto N, Kishimoto T. Interleukin-6 from bench to bedside. Nat Clin Pract Rheumatol 2006;2(11):619–26.
51) Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52(3):232–4.
52) De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum interleukin 6 is predictive of early funcional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013;40(4):435–46.
53) Benedetta Marigliano, Alessandra Soriano, Domenico Margiotta, Marta Vadacca, Antonella Afeltra. Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis. Autoimmunity Reviews 12 (2013) 1076–1084.
17 Views | 9 Downloads
How to Cite
Geethika, T., S. Kodat, and N. Thanusha. “A REVIEW ON INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS”. World Journal of Current Medical and Pharmaceutical Research, Vol. 1, no. 5, 1, pp. 138-42, https://wjcmpr.com/index.php/journal/article/view/31.